News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Joe Y. Chang on upcoming PTCOG 63: IMRT vs IMPT Phase III trials
Joe Y. Chang/X
May 21, 2025, 18:49

Joe Y. Chang on upcoming PTCOG 63: IMRT vs IMPT Phase III trials

Joe Y Chang, Professor, Clinical Section Chief at MD Anderson Cancer Center, shared a post on X:

“Join us at PTCOG 63 to explore cutting-edge particle therapy and novel Phase III randomized studies comparing IMRT and IMPT.
With advancements in LET optimization, immune modulation, we are moving PT into the new era.”

PTCOG 63

More posts featuring Joe Y Chang on OncoDaily.

cancer IMPT IMRT Joe Y Chang MD Anderson Cancer Center OncoDaily Oncology PTCOG 63
Special Coverage
Blog
Jul 3, 2025, 02:58
Maria Pefkianaki: It was an Honor to Participate in a Session At the 2nd Synergies Forum
Blog
Jul 2, 2025, 20:46
New EU-funded Project PredictAYA - European Cancer Organisation
Blog
Jul 2, 2025, 20:37
Jame Abraham: Thank you Mariam AlHilli for Hosting the Father of Targeted Therapy in Breast Cancer
Blog
Jul 2, 2025, 20:25
Wafik El-Deiry: Honored to Meet Christopher Macchio
Insight
Jul 2, 2025, 20:16
Supriya Peshin on Rare Metastatic Pathways of Renal Cell Carcinoma
Blog
Jul 2, 2025, 17:48
Riya Patel: First Day as GI Medical Oncologist at the Zuckerberg Cancer Center
Blog
Jul 2, 2025, 17:38
Sergio Cifuentes: Important Information for Colleagues from LATAM Interested in GI Oncology
Blog
Jul 2, 2025, 17:27
Sarah Sammons: Dana-Farber’s Breast Oncology Center and Dr. Waks Debates Standard of Care in Stage II/III Her2+ Breast Cancer
Blog
Jul 2, 2025, 17:12
Benjamin Schrank: I’ve Joined MD Anderson Cancer Center as an Assistant Professor and Physician-Scientist in Radiation Oncology
Blog
Jul 2, 2025, 16:59
Salvador Jaime-Casas: The promise and pitfalls of predictive biomarkers in mUC
Blog
Jul 2, 2025, 16:42
Katsuaki Maehara: TTF-1 is a New Marker to Identify Patients Best Suited for Lung Cancer KRAS Inhibitors 
Insight
Jul 2, 2025, 16:16
Paolo Tarantino: Randomized phase 2 trial of neoadjuvant ARX788 + Pyrotinib vs TCHP for HER2+ BC